Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
IMNM

IMNM - Immunome Inc Stock Price, Fair Value and News

16.04USD+0.04 (+0.25%)Market Closed

Market Summary

IMNM
USD16.04+0.04
Market Closed
0.25%

IMNM Alerts

  • 2 major insider buys recently.

IMNM Stock Price

View Fullscreen

IMNM RSI Chart

IMNM Valuation

Market Cap

961.9M

Price/Earnings (Trailing)

-4.15

Price/Sales (Trailing)

75.84

Price/Free Cashflow

-21

IMNM Price/Sales (Trailing)

IMNM Profitability

Return on Equity

-81.25%

Return on Assets

-72.56%

Free Cashflow Yield

-4.76%

IMNM Fundamentals

IMNM Revenue

Revenue (TTM)

12.7M

Rev. Growth (Yr)

-56.47%

Rev. Growth (Qtr)

-73.11%

IMNM Earnings

Earnings (TTM)

-232.0M

Earnings Growth (Yr)

-2.9K%

Earnings Growth (Qtr)

-39.79%

Breaking Down IMNM Revenue

Last 7 days

5.9%

Last 30 days

9.0%

Last 90 days

-28.6%

Trailing 12 Months

203.8%

How does IMNM drawdown profile look like?

IMNM Financial Health

Current Ratio

10.18

IMNM Investor Care

Shares Dilution (1Y)

390.94%

Diluted EPS (TTM)

-7.55

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202412.7M000
20234.0M7.3M10.7M14.0M
2022000622.0K

Tracking the Latest Insider Buys and Sells of Immunome Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 21, 2024
bienaime jean jacques
bought
27,139
13.5699
2,000
-
May 21, 2024
siegall clay b
bought
281,548
13.7784
20,434
president and ceo
May 20, 2024
siegall clay b
bought
1,106,520
13.907
79,566
president and ceo
Oct 02, 2023
rapp michael
acquired
1,499,990
5.91
253,806
-
Oct 02, 2023
siegall clay b
bought
999,996
5.91
169,204
president and ceo
Oct 02, 2023
prendergast franklyn g
acquired
-
-
60,840
-
Oct 02, 2023
turner bruce
bought
249,993
5.91
42,300
chief strategy officer
Jan 15, 2023
lefenfeld michael
acquired
55,500
4.00
13,875
-
Jan 15, 2023
rapp michael
acquired
70,000
4.00
17,500
-
Jan 15, 2023
wagenheim philip
acquired
35,000
4.00
8,750
-

1–10 of 31

Which funds bought or sold IMNM recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 24, 2024
Cetera Investment Advisers
new
-
3,038,060
3,038,060
0.01%
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
new
-
14,659,900
14,659,900
0.07%
May 16, 2024
COMERICA BANK
new
-
839
839
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
new
-
806,567
806,567
-%
May 16, 2024
JANE STREET GROUP, LLC
added
91.13
3,773,710
4,880,890
-%
May 15, 2024
AQR CAPITAL MANAGEMENT LLC
new
-
294,556
294,556
-%
May 15, 2024
DEUTSCHE BANK AG\
new
-
11,155
11,155
-%
May 15, 2024
STATE STREET CORP
added
556
4,625,730
4,953,050
-%
May 15, 2024
WELLINGTON MANAGEMENT GROUP LLP
new
-
1,351,200
1,351,200
-%
May 15, 2024
MORGAN STANLEY
added
1,129
3,557,060
3,687,120
-%

1–10 of 47

Are Funds Buying or Selling IMNM?

Are funds buying IMNM calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own IMNM
No. of Funds

Unveiling Immunome Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 12, 2024
alpine global management, llc
0.45%
192,333
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G
Oct 12, 2023
ecor1 capital, llc
9.1%
3,879,415
SC 13G
Oct 12, 2023
barchas isaac
3.4%
-
SC 13D
Oct 12, 2023
immunome aggregator, lp
8.1%
0
SC 13D
Oct 12, 2023
redmile group, llc
9.1%
3,879,415
SC 13G
Jul 07, 2023
morphimmune inc.
20%
2,659,508
SC 13D
Feb 14, 2023
prentice capital management, lp
4.11%
498,145
SC 13G/A
Jan 17, 2023
alpine global management, llc
5.9%
718,235
SC 13G/A
Feb 14, 2022
rapp michael
9.6%
1,181,575
SC 13G/A

Recent SEC filings of Immunome Inc

View All Filings
Date Filed Form Type Document
Jun 13, 2024
8-K
Current Report
May 22, 2024
4
Insider Trading
May 21, 2024
4
Insider Trading
May 17, 2024
4
Insider Trading
May 14, 2024
10-Q
Quarterly Report
May 14, 2024
424B5
Prospectus Filed
May 14, 2024
8-K
Current Report
Apr 30, 2024
8-K
Current Report
Apr 29, 2024
4
Insider Trading
Apr 29, 2024
3
Insider Trading

Peers (Alternatives to Immunome Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
55.6B
6.8B
13.11% 15.14%
-9.32
8.12
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.2B
2.0B
8.19% -19.39%
-60.95
10.1
75.20% 68.82%
16.0B
2.5B
5.74% -10.79%
77.84
6.47
13.74% 186.89%
14.1B
3.8B
9.90% 2.05%
18.89
3.74
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.17% 71.70%
-9.93
48.09
54.84% -28.31%
5.2B
524.1M
3.28% -53.81%
-12.38
9.85
394.93% 39.61%
3.4B
251.0M
-6.27% -10.41%
-11.62
13.72
73.58% -86.73%
3.3B
240.7M
15.67% -25.01%
-6.96
12.77
-1.03% -213.92%
2.5B
813.8M
1.62% -37.45%
-1.5K
3.07
56.43% 98.83%
2.1B
996.6M
11.65% 94.95%
-5.3
2.12
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-7.16% 29.42%
27.77
4.4
60.38% -34.49%
564.4M
881.7K
22.84% 567.64%
-16.72
481.06
-77.61% 33.36%
244.6M
4.2M
-17.34% 57.33%
-1.96
58.8
-66.30% 48.24%
22.1M
2.1M
36.17% 271.01%
-0.95
7.61
-13.45% 69.54%

Immunome Inc News

Latest updates
MarketBeat11 Jun 202409:53 pm
Simply Wall St22 May 202407:00 am
Investing.com22 May 202407:00 am
Yahoo Finance21 May 202407:00 am

Immunome Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q3
Revenue-73.1%1,0293,8263,5654,2632,3641,493622-
Operating Expenses35.4%133,32898,4798,19810,0366,8357,7878,534-
  S&GA Expenses-25.3%6,0058,0404,3754,3202,9223,5353,309-
  R&D Expenses59.5%15,3699,6373,8235,7163,9134,2525,225-
Interest Expenses39.0%2,8072,0192882162011.001.00-
Net Income-39.8%-129,492-92,634-4,345-5,557-4,270-7,786-8,533-
Net Income Margin-140.1%-18.29*-7.62*-2.06*-3.57*-7.43*-59.32*--
Free Cashflow25.1%-13,334-17,808-8,650-6,00824,067-6,755-7,571-8,230
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32019Q4
Assets115.3%32014993.0041.0048.0024.0031.0039.0048.0058.0063.0064.0043.0045.0012.005.00
  Current Assets116.5%31314591.0040.0047.0023.0029.0038.0046.0057.0061.0063.0041.0043.007.003.00
    Cash Equivalents173.3%27099.0091.0038.0044.0020.0027.0035.0043.0049.0056.0060.0036.0040.007.003.00
  Net PPE107.5%4.002.001.001.001.001.001.001.001.001.001.001.001.002.002.002.00
Liabilities19.3%34.0029.0087.0032.0034.007.007.009.0010.0010.008.004.005.003.0013.002.00
  Current Liabilities41.0%31.0022.0023.0026.0025.007.007.009.0010.0010.008.004.005.003.005.002.00
Shareholder's Equity138.2%2861206.009.0014.0017.0023.0030.0038.0048.0055.0061.0038.0041.00--
  Retained Earnings-58.1%-352-222-130-125-120-116-108-99.70-90.80-79.10-71.25-63.53-58.30-54.39-50.30-36.60
  Additional Paid-In Capital86.1%63834313613513413313113012912712612496.0096.001.001.00
Shares Outstanding38.0%60.0043.0012.0012.0012.0012.0012.0012.0012.0012.0011.0011.0011.00---
Float----76.00---34.00---182----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q3
Cashflow From Operations36.0%-11,170-17,459-8,614-5,66824,173-6,683-7,571-8,060-6,376-6,805-4,145-3,741-3,535-6,062-2,528-1,480-2,064--
  Share Based Compensation-25.1%2,1592,8831,0831,0331,2241,3551,3401,3271,3101,2191,15574932531911739.00146--
Cashflow From Investing-24.1%-37,231-30,002-36.00-340-106-72.00--170-6.00-14.00-26.00-8.00-31.00-46.00-124-361-55.00--
Cashflow From Financing295.4%219,44555,49960,875-34.00---32.00-19558527,30276.0039,130-39310,362844--
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

IMNM Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Condensed Consolidated Statements of Operations and Comprehensive Loss  
Collaboration revenue$ 1,029$ 2,364
Operating expenses:  
In-process research and development111,954 
Research and development15,3693,913
General and administrative6,0052,922
Total operating expenses133,3286,835
Loss from operations(132,299)(4,471)
Interest income2,807201
Net loss$ (129,492)$ (4,270)
Per share information:  
Net loss per share, Basic$ (2.51)$ (0.35)
Net loss per share, Diluted$ (2.51)$ (0.35)
Weighted-average shares outstanding, Basic51,544,38312,182,478
Weighted-average shares outstanding, Diluted51,544,38312,182,478
Comprehensive loss:  
Net loss$ (129,492)$ (4,270)
Unrealized loss on marketable securities(18) 
Comprehensive loss$ (129,510)$ (4,270)

IMNM Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 269,723$ 98,679
Marketable securities39,98339,463
Prepaid expenses and other current assets3,6206,561
Total current assets313,326144,703
Property and equipment, net4,3022,073
Operating right-of-use assets1,4581,564
Restricted cash100100
Other long-term assets568100
Total assets319,754148,540
Current liabilities:  
Accounts payable7,1793,311
Accrued expenses and other current liabilities10,8448,025
Deferred revenue, current12,74510,493
Total current liabilities30,76821,829
Deferred revenue, non-current2,2085,489
Operating lease liabilities, net of current portion1,2061,340
Total liabilities34,18228,658
Commitments and contingencies (Note 6)
Stockholders' equity:  
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.0001 par value; 300,000,000 and 200,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; 59,694,243 and 43,251,778 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively64
Additional paid-in capital637,861342,663
Accumulated other comprehensive income422
Accumulated deficit(352,299)(222,807)
Total stockholders' equity285,572119,882
Total liabilities and stockholders' equity$ 319,754$ 148,540
IMNM
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01 that targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
 CEO
 WEBSITEhttps://immunome.com
 INDUSTRYBiotechnology
 EMPLOYEES37

Immunome Inc Frequently Asked Questions


What is the ticker symbol for Immunome Inc? What does IMNM stand for in stocks?

IMNM is the stock ticker symbol of Immunome Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Immunome Inc (IMNM)?

As of Thu Jun 13 2024, market cap of Immunome Inc is 961.9 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IMNM stock?

You can check IMNM's fair value in chart for subscribers.

What is the fair value of IMNM stock?

You can check IMNM's fair value in chart for subscribers. The fair value of Immunome Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Immunome Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IMNM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Immunome Inc a good stock to buy?

The fair value guage provides a quick view whether IMNM is over valued or under valued. Whether Immunome Inc is cheap or expensive depends on the assumptions which impact Immunome Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IMNM.

What is Immunome Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, IMNM's PE ratio (Price to Earnings) is -4.15 and Price to Sales (PS) ratio is 75.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IMNM PE ratio will change depending on the future growth rate expectations of investors.